The company reported continued growth in the sales of its ethical drug for the treatment of MS by 22% to $353 million.
A study on Teva Pharmaceutical Industries Ltd.'s (Nasdaq: TEVA; TASE: TEVA) Copaxone presented today at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Madrid, Spain demonstrated that antibodies to Copaxone developed in all patients with multiple sclerosis (MS) treated with the drug, but did not interfere with its efficacy. The study shows noninterference with Copaxone also for the long term.
“Neutralizing antibodies against interferon beta are therefore an important issue for MS management, as their development appears to diminish their clinical efficacy,” said Professor Dimitrios Karussis, Department of Neurology, Hadassah University Hospital, Ein-Karem Jerusalem. “Our data confirms that antibodies to Copaxone which develop in all patients do not neutralize the drug’s biological activity and do not compromise its established sustained long term effectiveness.” he added.
Copaxone is Teva's leading ethical drug. The company reported continued growth in the sales of its ethical drug for the treatment of MS by 22% to $353 million.
Published by Globes [online], Israel business news - www.globes.co.il - on September 28, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006